📰 Human Use News
Page 119 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
August 30, 2022
Teva announced today that the European Commission has granted marketing authorization for RANIVISIO, a biosimilar ranibizumab, for the treatment of age-related macular...
August 29, 2022
AMSTERDAM, the Netherlands, MUNICH, Germany and ZUG, Switzerland, August 29, 2022 / B3C newswire / -- Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorization (“MA”) to Ranivisio® (Ra...
August 29, 2022
DGAP-News: Formycon AG / Key word(s): Regulatory Approval European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizum...
August 29, 2022
One of the major factors driving market expansion is a huge increase in migraine cases. Also, the market is benefiting from improved reimbursement policies...
August 29, 2022
DGAP-News: Formycon AG / Key word(s): Regulatory ApprovalEuropean Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2 (news with additional features)29.08.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release, August 29, 2022...
August 29, 2022
29.08.2022 - DGAP-News: Formycon AG / Key word(s): Regulatory Approval European Commission approves FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis2 (news with additional features) 29.08.2022 / 08:00 CET/CEST The issuer is solely ... Seite 1
August 26, 2022
Formycon AG / Key word(s): Regulatory ApprovalFormycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2 26-Aug-2022 / 16:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely...
August 26, 2022
Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been granted an extension to its existing UK approval, for 12- to 17-year-olds. This extension has been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).
August 26, 2022
26.08.2022 - DGAP-Ad-hoc: Formycon AG / Key word(s): Regulatory Approval Formycon announces EU-Approval of FYB201/Ranivisio1 a biosimilar to Lucentis2 26-Aug-2022 / 16:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation ... Seite 1
August 26, 2022
The Medicines and Healthcare products Regulatory Agency has concluded that Nuvaxovid is safe and effective in this age group